$0.775
+0 (+0%)
At Close: Dec 06, 2023
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
12:00pm, Thursday, 07'th Sep 2023
Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
09:15am, Monday, 21'st Aug 2023
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
01:43pm, Friday, 04'th Aug 2023
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,93
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
08:30am, Wednesday, 02'nd Aug 2023
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
08:30am, Friday, 28'th Jul 2023
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unres
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
07:30am, Monday, 26'th Jun 2023
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Phar
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
07:30am, Thursday, 22'nd Jun 2023
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis P
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
04:26pm, Thursday, 25'th May 2023
SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmac
Adamis Pharmaceuticals Announces Reverse Stock Split
12:00pm, Friday, 19'th May 2023
SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse sto
Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript
06:32pm, Monday, 15'th May 2023
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2023 Earnings Conference Call May 15, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - C
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
04:47pm, Monday, 15'th May 2023
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET
Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript
04:50pm, Friday, 17'th Mar 2023
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q4 2022 Results Conference Call March 16, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto -
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
04:24pm, Thursday, 16'th Mar 2023
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
04:01pm, Tuesday, 14'th Mar 2023
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing produc
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
08:30am, Tuesday, 14'th Mar 2023
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing produc
Sign In
Buy ADMP